RUA: FY24 saw revenue growth, capital needs, and global expansion plans for Rua Bioscience

About this update from Rua Bioscience Ltd.

Rua Bioscience reported FY24 revenue growth, ongoing losses, and a capital-light international expansion strategy. Shareholders voted on auditor remuneration and a new share issue, with plans to raise NZ$3.1m and target new markets in FY25.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Rua Bioscience Ltd.